Pilot study to test the safety, tolerability and feasibility of dulaglutide during a low-energy diet for weight loss and improved glycaemic control.

Shand JAD, Young S, Verster F, Peters C

BMJ nutrition, prevention & health22 Nov 2023Cited by 7 (Europe PMC)

PMID38264361PMCIDPMC10800248DOI10.1136/bmjnph-2023-000733PepBankPUB-38264361

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

01HumanNot a test of Dulaglutide (Trulicity) aloneNon-randomized trialSafety outcome
In people with obesity and diabetes, the dulaglutide and low energy diet intervention was well tolerated.
In plain wordsIn people with obesity and diabetes, the combined dulaglutide and low energy diet intervention was well tolerated.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableTolerability
Study
n: not reported in source
Analysis
Primary
Outcome group
Adverse events · Metabolic and weight
Source sentences
Summary
The intervention was well tolerated.
4 context sentences(design, population, supporting numbers)
Summary · context
We enrolled individuals with type 2 diabetes and obesity from a tertiary diabetes service in Auckland, New Zealand.
Summary · context
Owing to their higher rates of diabetes and poorer diabetes-related health outcomes, we preferentially enrolled Māori and Pacific individuals.Participants underwent 2 weeks of dulaglutide run-in followed by 12 weeks of the combination of dulaglutide and low energy diet.
Summary · context
The primary endpoints were the proportion of people successfully completing the dietary intervention and the rates and types of adverse events.
Summary · context
Secondary outcomes were changes in weight, glycaemic control, quality of life and biochemical parameters.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3826436101
02HumanNot a test of Dulaglutide (Trulicity) aloneNon-randomized trialSafety outcome
In people with obesity and diabetes, mild side effects were common early in the combined intervention but generally improved.
In plain wordsIn people with obesity and diabetes, mild side effects during dulaglutide and a low energy diet generally improved.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseMild side effects
Study
n: not reported in source
Analysis
Primary
Outcome group
Adverse events · Metabolic and weight
Source sentences
Summary
Mild side effects were common during the first 2 weeks of the intervention but generally improved over the study period.
4 context sentences(design, population, supporting numbers)
Summary · context
We enrolled individuals with type 2 diabetes and obesity from a tertiary diabetes service in Auckland, New Zealand.
Summary · context
Owing to their higher rates of diabetes and poorer diabetes-related health outcomes, we preferentially enrolled Māori and Pacific individuals.Participants underwent 2 weeks of dulaglutide run-in followed by 12 weeks of the combination of dulaglutide and low energy diet.
Summary · context
The primary endpoints were the proportion of people successfully completing the dietary intervention and the rates and types of adverse events.
Summary · context
Secondary outcomes were changes in weight, glycaemic control, quality of life and biochemical parameters.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3826436102
03HumanNot a test of Dulaglutide (Trulicity) aloneNon-randomized trialOther
In people with obesity and diabetes receiving dulaglutide, eighty-nine per cent completed the low energy dietary intervention.
In plain wordsIn people with obesity and diabetes receiving dulaglutide, eighty-nine per cent completed the low energy diet intervention.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableDietary intervention completion
Study
n: not reported in source
Analysis
Primary
Outcome group
Treatment adherence and retention · Metabolic and weight
Measurements
Completion of dietary intervention
89%
12-week dietary intervention
Source sentences
Summary
Eighty-nine per cent of participants completed the 12-week dietary intervention.
4 context sentences(design, population, supporting numbers)
Summary · context
We enrolled individuals with type 2 diabetes and obesity from a tertiary diabetes service in Auckland, New Zealand.
Summary · context
Owing to their higher rates of diabetes and poorer diabetes-related health outcomes, we preferentially enrolled Māori and Pacific individuals.Participants underwent 2 weeks of dulaglutide run-in followed by 12 weeks of the combination of dulaglutide and low energy diet.
Summary · context
The primary endpoints were the proportion of people successfully completing the dietary intervention and the rates and types of adverse events.
Summary · context
Secondary outcomes were changes in weight, glycaemic control, quality of life and biochemical parameters.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3826436103
04HumanNot a test of Dulaglutide (Trulicity) aloneNon-randomized trialEfficacy outcome
In people with obesity and diabetes, the dulaglutide and low energy diet intervention produced average weight loss of 9.5 kg.
In plain wordsIn people with obesity and diabetes, average weight loss during dulaglutide and a low energy diet was 9.5 kg.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseWeight loss
Study
n: not reported in source
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Measurements
Weight loss
9.5 kg
combined intervention
Source sentences
Summary
Participants achieved an average weight loss of 9.5 kg and a mean reduction in haemoglobin A_1c of 15.8 mmol/mol.
4 context sentences(design, population, supporting numbers)
Summary · context
We enrolled individuals with type 2 diabetes and obesity from a tertiary diabetes service in Auckland, New Zealand.
Summary · context
Owing to their higher rates of diabetes and poorer diabetes-related health outcomes, we preferentially enrolled Māori and Pacific individuals.Participants underwent 2 weeks of dulaglutide run-in followed by 12 weeks of the combination of dulaglutide and low energy diet.
Summary · context
The primary endpoints were the proportion of people successfully completing the dietary intervention and the rates and types of adverse events.
Summary · context
Secondary outcomes were changes in weight, glycaemic control, quality of life and biochemical parameters.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3826436104
05HumanNot a test of Dulaglutide (Trulicity) aloneNon-randomized trialEfficacy outcome
In people with obesity and diabetes, HbA1c fell by 15.8 mmol/mol during the dulaglutide and low energy diet intervention.
In plain wordsIn people with obesity and diabetes, HbA1c fell by 15.8 mmol/mol during dulaglutide and a low energy diet.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c reduction
Study
n: not reported in source
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Measurements
HbA1c reduction
15.8 mmol/mol
combined intervention
Source sentences
Summary
Participants achieved an average weight loss of 9.5 kg and a mean reduction in haemoglobin A_1c of 15.8 mmol/mol.
4 context sentences(design, population, supporting numbers)
Summary · context
We enrolled individuals with type 2 diabetes and obesity from a tertiary diabetes service in Auckland, New Zealand.
Summary · context
Owing to their higher rates of diabetes and poorer diabetes-related health outcomes, we preferentially enrolled Māori and Pacific individuals.Participants underwent 2 weeks of dulaglutide run-in followed by 12 weeks of the combination of dulaglutide and low energy diet.
Summary · context
The primary endpoints were the proportion of people successfully completing the dietary intervention and the rates and types of adverse events.
Summary · context
Secondary outcomes were changes in weight, glycaemic control, quality of life and biochemical parameters.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3826436105
06HumanNot a test of Dulaglutide (Trulicity) aloneNon-randomized trialEfficacy outcome
In people with obesity and diabetes, quality of life remained unchanged during the dulaglutide and low energy diet intervention.
In plain wordsIn people with obesity and diabetes, quality of life did not change during dulaglutide and a low energy diet.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeQuality of life
Study
n: not reported in source
Analysis
Secondary
Outcome group
Quality of life · Whole body
Source sentences
Summary
Quality of life metrics were unchanged.
4 context sentences(design, population, supporting numbers)
Summary · context
We enrolled individuals with type 2 diabetes and obesity from a tertiary diabetes service in Auckland, New Zealand.
Summary · context
Owing to their higher rates of diabetes and poorer diabetes-related health outcomes, we preferentially enrolled Māori and Pacific individuals.Participants underwent 2 weeks of dulaglutide run-in followed by 12 weeks of the combination of dulaglutide and low energy diet.
Summary · context
The primary endpoints were the proportion of people successfully completing the dietary intervention and the rates and types of adverse events.
Summary · context
Secondary outcomes were changes in weight, glycaemic control, quality of life and biochemical parameters.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3826436106

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.